Apilimod Dimesylate not checked
IRulya Therapeutics Inc. · LAM-002A
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.”In the company’s words, NCT04446377 on ClinicalTrials.gov
- Tested for
- COVID-19 Disease, Amyotrophic Lateral Sclerosis, ALS, Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
- Main trialPhase 2
- “This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.”In the company’s words, NCT04446377 on ClinicalTrials.gov
- Other names
- LAM-002A
Other drugs for COVID-19 Disease
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 24 Mar 2021 | A Study of LAM-002A for the Prevention of Progression of COVID-19 | |
| Phase 2Completed | 11 Jan 2023 | Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis | |
| Phase 1Completed | 9 Mar 2020 | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026